Aclaris Therapeutics, Inc.

US$3.90As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ACRSHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (15.57%)
Div yield —
ROE (55.51%)
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM 54.76%
Mkt cap US$618.6M
ROIC (38.85%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.44
13.84%
(4.91%)
Hold 10|2|12|3|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.07
0.07
0.07
0.07
(6.45%)
2.18%
4.74%
12.01%
Revenue$M
63.01
63.94
65.41
68.46
4.86%
6.24%
5.60%
9.89%
Peers (US$618.6M)
Cap (US$)
PE
637.7M
—
628.6M
1.778x
604.4M
—
Capital
TTM
5Y
10Y
Leveragex
0.532
0.208
0.199
EBIT/Intx
1.234
2.206
2.231
Own earn%
(2.54)
(61.96)
(48.67)
Sh yield%
37.25
31.20
30.66
Owners
Insiders/Inst%
13.97
51.67
Short interest%
3.71
SBC / revenue%
3.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
23–28
$1 testx
—
Incr. ROIC%
−1